In July 2015, two women filed lawsuits against the pharmaceutical giant
GlaxoSmithKline. The lawsuits allege that their babies were born with
congenital heart defects after the women took the medication Zofran during
their pregnancies. They claim GlaxoSmithKline knowingly marketed this
dangerous drug to OBGYNs though the drug was never approved for use in
The mothers, both residents of Ohio took Zofran during their first trimester
of pregnancy in the mid-to-late 1990s; to help them combat the pregnancy-induced
nausea and vomiting. Zofran, however, was never tested on pregnant women
and was only approved in 1991 as a remedy for nausea and vomiting associated
The first Plaintiff claims that her daughter was born on July 3, 1999 and
initially confined to the NICU with lung problems. For two years, her
breathing problems did not improve – until she was finally diagnosed
with a severe heart defect, known as an atrial septal defect. The defect
had irreparably damaged the little girl's lungs and she would now
require extensive open-heart surgery. Her heart defect is now repaired,
but her breathing difficulties have continued because of the lung tissue damage.
The second Plaintiff claims that her daughter was born in 1999 with a ventricular
septal defect that was not identified until she was four years old. This
defect forced the heart to strain harder to deliver oxygen and vital nutrients
to the body's organs and tissues. To date, the birth defect has not
been resolved, nor has it closed on its own.
Zofran Manufacturers Purposefully Hid Risks from Public
Plaintiffs claim that Zofran manufacturers purposefully hid the risks associated
with Zofran, while simultaneously promoting this drug to obstetricians
and gynecologists. They told the OBGYN community that it was a safe morning
sickness treatment, despite never being tested on pregnant women. This
unapproved promotion was a direct violation of federal law.
According to lawsuits, Zofran manufacturers concealed numerous warning
signs that their drug was associated with major birth defects. They even
failed to submit a number of birth defect reports to the FDA. Two studies
in particular have been referenced in lawsuits. Both studies have found
increased risk for "hole in the heart" defects, such as atrial
septal defects and ventricular septal defects, when mothers use Zofran
during pregnancy – especially during the first trimester.
Sadly, they are not alone – at least 34 other Plaintiffs have filed
Zofran lawsuits across the country claiming that Zofran causes birth defects.
Contact Our National Dangerous Drug Lawyers
If you took Zofran during pregnancy and your baby was born with a congenital
defect, it is important to speak one of the experienced national dangerous
drug attorneys at Golomb & Honik immediately. Our lawyers can answer
all your questions regarding the current Zofran litigation and determine
if you are eligible to file a lawsuit against the manufacturers of Zofran.
To learn more about your legal options or to schedule a free consultation
call the Philadelphia class action lawyers at Golomb & Honik today at
1-800-355-3300 or 1-215-985-9177 or fill out our confidential
The national dangerous drug lawyers at Golomb & Honik have successfully
represented individuals in Philadelphia, Pennsylvania, New Jersey, and
throughout the United States.